Congenix Adds Russian Presence to Health Decisions' Agile Clinical Network
Health Decisions announces that Moscow-based CRO Congenix has become a certified member of the Agile Clinical Network-a community of research partners with the goal of higher efficiency standards in complex global studies.
Congenix has received certification after completing "rigorous" training in Agile Clinical development techniques.
“Conducting global, multi-center trials with a network of regionally focused CROs offers many advantages over a single large CRO with international offices,” said Vladimir V. Novakovskiy, M.D., Ph.D., managing director, Clinical Operations and Regulatory Affairs, Congenix, LLP. “We look forward to bringing our extensive knowledge of Eastern Europe and Russia to the Agile Clinical Network to better assist sponsors with assessing investigators, cooperating with the local regulatory bodies, and recruiting study subjects.”
According to Dr. Novakovskiy, Eastern Europe and Russia offer sponsors high recruitment rates, an excellent selection of high-quality investigational sites, and lower cost per patient compared to Western Europe and the U.S. Other benefits include Russia’s highly centralized healthcare system and a large percentage of treatment-naïve patients.
A UK-registered CRO with offices in Moscow and Hercules, CA, USA, Congenix offers Phase I to IV services including regulatory affairs, clinical monitoring, project management, investigational site management, study supplies custom clearance, warehousing and distribution. Working within the Agile network, Congenix will have access to Health Decisions’ and other members’ high-efficiency data management systems, biostatistics expertise, medical writers, advanced data collection tools, and real-time reporting capabilities, as well as regional infrastructure around the world.
"We welcome Congenix to the Agile Clinical Network and look forward to our working together on global trials that will maximize efficiency and transparency,” said Rick Farris, Chief Operations Officer at Health Decisions. “Congenix will be a great asset to our Network as we expand its mission to deliver accurate trial results...”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
